

30 July 2026

Gastroenterology New Patients

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of February, March and April (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st December 2025, they are not classed as a new patient for the purposes of this question.

Adult Gastroenterology Service

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	0	0	0
Adalimumab [All Biosimilar]	10	10	0
Etrasimod	0		0
Filgotinib	<5		<5
Golimumab [Simponi]	<5	<5	0
Golimumab [All Biosimilar]	0	0	0
Guselkumab	19	16	<5
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	12	<10	<10
Mirikizumab	12	0	12
Ozanimod	<5		<5
Risankizumab	11	<10	<5
Tofacitinib	0		0
Upadacitinib	12	<5	<10
Ustekinumab [Stelara]	0	0	0
Ustekinumab [All Biosimilar]	65	50	15
Vedolizumab	13	<5	10

30 July 2026

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

Paediatric Gastroenterology Service

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]			
Adalimumab [All Biosimilar]			
Etrasimod			
Filgotinib			
Golimumab [Simponi]			
Golimumab [All Biosimilar]			
Guselkumab			
Infliximab [Remicade]			
Infliximab [All Biosimilar]	24	15	9
Mirikizumab			
Ozanimod			
Risankizumab			
Tofacitinib			
Upadacitinib	<5	<5	0
Ustekinumab [Stelara]			
Ustekinumab [All Biosimilar]	<5	0	<5
Vedolizumab			

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.